{"id":1056,"date":"2022-02-22T19:50:10","date_gmt":"2022-02-22T19:50:10","guid":{"rendered":"https:\/\/glossaire.myeloma.ca\/?glossaire=placebo-2"},"modified":"2022-02-22T19:50:10","modified_gmt":"2022-02-22T19:50:10","slug":"placebo-2","status":"publish","type":"glossary","link":"https:\/\/myeloma.ca\/fr\/glossaire\/placebo-2\/","title":{"rendered":"Placebo"},"content":{"rendered":"<p>Substance inerte (inactive) souvent utilis\u00e9e dans les essais cliniques \u00e0 des fins de comparaison avec un m\u00e9dicament exp\u00e9rimental.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Substance inerte (inactive) souvent utilis\u00e9e dans les essais cliniques \u00e0 des fins de comparaison avec un m\u00e9dicament exp\u00e9rimental.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"template":"","glossary-cat":[],"class_list":["post-1056","glossary","type-glossary","status-publish","hentry"],"acf":[],"aioseo_notices":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/glossary\/1056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/glossary\/1056\/revisions"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=1056"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/glossary-cat?post=1056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}